# Efficacy and Safety of MEDI6570 in Patients With a History of Myocardial Infarction

Study · id `cardio:ct-nct04610892` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04610892](<https://clinicaltrials.gov/study/NCT04610892>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT04610892

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 423 participants.

## Technical summary

Registry record NCT04610892. Randomized; quadruple masking; primary purpose treatment. Start 2020-11-04 (actual); primary completion 2023-11-08 (actual). Results posted on 2025-02-21.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 423 participants (enrolled count; ClinicalTrials.gov record NCT04610892, source copy `cardio:ctgov-nct04610892-2025-02-21`, retrieved 2026-10-31)
- Started: 2020-11-04 (actual) (ClinicalTrials.gov record NCT04610892, source copy `cardio:ctgov-nct04610892-2025-02-21`, retrieved 2026-10-31)
- Primary completion: 2023-11-08 (actual) (ClinicalTrials.gov record NCT04610892, source copy `cardio:ctgov-nct04610892-2025-02-21`, retrieved 2026-10-31)
- Completion: 2023-11-08 (actual) (ClinicalTrials.gov record NCT04610892, source copy `cardio:ctgov-nct04610892-2025-02-21`, retrieved 2026-10-31)
- Results first posted: 2025-02-21 (ClinicalTrials.gov record NCT04610892, source copy `cardio:ctgov-nct04610892-2025-02-21`, retrieved 2026-10-31)
- Countries: United States; Australia; Canada; Czechia; Hungary; Italy; Japan; Netherlands; Poland; Spain; United Kingdom (ClinicalTrials.gov record NCT04610892, source copy `cardio:ctgov-nct04610892-2025-02-21`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04610892-2025-02-21`, retrieved 2026-10-31)

## The registry's words

- Brief title: Efficacy and Safety of MEDI6570 in Patients With a History of Myocardial Infarction
- Acronym: GOLDILOX
- Condition: Coronary Heart Disease (CHD)
- Intervention (Biological): MEDI6570
- Intervention (Biological): Placebo
- Lead sponsor: AstraZeneca
- Lead sponsor class: INDUSTRY
- Collaborator: The TIMI Study Group
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Atherosclerosis (`cardio:atherosclerosis`)
- Registry lists this organization as the lead sponsor: AstraZeneca (`cardio:astrazeneca`)
- Registry lists this organization as a collaborator: The TIMI Study Group (`cardio:org-the-timi-study-group`)

## Provenance

Content hash: fbddec3c04df1446f52704fde48d70a2b79e408a12ac239beefc10f4deb78967
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
